Skip to content

Effect of Testosterone Pretreatment in POR

Therapeutic Effect of Prolonged Testosterone Pretreatment in Women With Poor Ovarian Response: a Randomized Control Trial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04602143
Enrollment
165
Registered
2020-10-26
Start date
2018-02-16
Completion date
2020-06-30
Last updated
2020-10-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility

Brief summary

This study compared the therapeutic effect of 4- and 6-week TTG application before controlled ovarian hyperstimulation (COH) in POR.

Detailed description

This randomized control trial (RCT) was conducted between January 2018 and September 2019 at the National Center for Reproductive Medicine, Hanoi, Vietnam. The eligibility of a total of 165 women with POR, undergoing IVF treatment, to be enrolled in the study was assessed. Inclusion criteria included patients who met at least two of the following criteria: (i) having one previous IVF/ intracytoplasmic sperm injection (ICSI) cycle with ≤ 3 oocytes recruited; (ii) AFC ≤ 5-7; and (iii) anti-Mullerian hormone (AMH) ≤ 0.5 - 1.1 ng/mL were enrolled. Exclusion criteria included donated gamete IVF cycles, thyroid disease, liver and kidney dysfunction, and abnormal genitalia. After screening, eligible patients were randomly allocated into two TTG intervention groups (4-week and 6-week groups) and one control group through a manual lottery. Allocation concealment was by sequentially numbered, opaque, sealed envelopes. All participants were blinded to group assignment, but researchers were not blinded. Serum testosterone are measured before treatment. Durations of androgen supplement are 4 or 6-weeks. After completing the pretreatment, patients are asked to come back when they have menses to begin IVF treatment. Serum testosterone is measured again after the pretreatment in both groups. Patients will be interviewed for side effects and compliance of treatment. After treatment, patients in both group undergo IVF treatment. IVF treatment will then be performed for all patients, according to the current hospital treatment protocols. Patients will be followed up at least until 12th week of gestation, if they have positive pregnancy test after embryo transfer. Data were analyzed using STATA software version 14.0 (Stata Corporation, College Station, TX, USA). Data were analyzed on an intention-to-treat basis. Proportions, means, and standard deviations (SDs) were examined and presented for selected baseline variables by treatment group. Comparisons of baseline characteristics and outcomes by treatment group were performed with the use of ANOVA for continuous variables and a chi-square test for proportions. A Bonferroni correction was used for multiple testing, in which the resulting P-value was multiplied by the number of tests that measured similar constructs. Multivariable logistic regressions were used to quantify the effects of the treatment group, adjusted for all potential confounders including maternal age, body mass index (BMI), infertility duration, primary or secondary infertility, and history of IVF treatment. All statistical tests were two-sided, and P values \< 0.05 were considered statistically significant.

Interventions

DRUGTestosterone gel

Apply 12.5mg testosterone gel to the abdomen and rub on with one finger, once a day, in the morning, then allow sites to dry and cover with clothing. Continue the treatment for 4 or 6 weeks until next IVF treatment.

Sponsors

National Hospital of Obstetrics and Gynecology
CollaboratorOTHER
Hanoi Medical University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Masking description

participantes are not aware of treatment groups

Eligibility

Sex/Gender
FEMALE
Age
20 Years to 47 Years
Healthy volunteers
No

Inclusion criteria

patients who met at least two of the following criteria * Having one previous IVF/ intracytoplasmic sperm injection (ICSI) cycle with ≤ 3 oocytes recruited. * AFC ≤ 5 - 7. * Anti-Mullerian hormone (AMH) ≤ 0.5 - 1.1 ng/mL.

Exclusion criteria

* donated gamete IVF cycles * Thyroid disease * Liver and kidney dysfunction * Abnormal genitalia

Design outcomes

Primary

MeasureTime frameDescription
Number of oocytes retrieved30 minutes after oocyte retrieval completeThe main outcomes of our study were the total number of retrieved

Secondary

MeasureTime frameDescription
Pregnancy rates.14 days after embryo transferPregnancy was defined as positive when the serum beta-hCG level was ≥ 50 IU/L
clinical pregnancy rates.4 weeks after embryo transferClinical pregnancy was defined as the presence of a gestational sac identified by transvaginal ultrasound
Ongoing pregnancy ratesafter 12 weeks of gestationOngoing pregnancy was defined as a viable intrauterine pregnancy after 12 weeks of gestation.

Countries

Vietnam

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026